UNLABELLED: Despite known ototoxic effects of aminoglycoside (AG) antibiotics, audiological assessment is not routinely undertaken in UK CF patients. Consequently, the incidence of hearing loss is not well established. OBJECTIVE: To document the incidence of hearing loss in cystic fibrosis (CF) children. DESIGN: Hearing function of 45 children from Great Ormond Street Hospital was assessed using pure-tone audiometry up to 20kHz and DPOAEs up to 8kHz. STUDY SAMPLE: 39/45 of participants had received intravenous (IV) AGs, 23 of which received repeated IV AGs every 3 months. RESULTS: In this high exposure group, 8 (21%) had clear signs of ototoxicity; average 8-20kHz thresholds were elevated by ∼50dB and DPOAE amplitudes were >10dB lower at f2 3.2-6.3 kHz. The remaining 31/39 (79%) of AG exposed patients had normal, even exceptionally good hearing. The 21% incidence of ototoxicity we observed is substantial and higher than previously reported. However, our finding of normal hearing in children with equal AG exposure strongly suggests that other unknown factors, possibly genetic susceptibility, influence this outcome. CONCLUSIONS: We recommend comparable auditory testing in all CF patients with high AG exposures. Genetic analysis may help explain the dichotomy in response to AGs found.
UNLABELLED: Despite known ototoxic effects of aminoglycoside (AG) antibiotics, audiological assessment is not routinely undertaken in UK CFpatients. Consequently, the incidence of hearing loss is not well established. OBJECTIVE: To document the incidence of hearing loss in cystic fibrosis (CF) children. DESIGN: Hearing function of 45 children from Great Ormond Street Hospital was assessed using pure-tone audiometry up to 20kHz and DPOAEs up to 8kHz. STUDY SAMPLE: 39/45 of participants had received intravenous (IV) AGs, 23 of which received repeated IV AGs every 3 months. RESULTS: In this high exposure group, 8 (21%) had clear signs of ototoxicity; average 8-20kHz thresholds were elevated by ∼50dB and DPOAE amplitudes were >10dB lower at f2 3.2-6.3 kHz. The remaining 31/39 (79%) of AG exposed patients had normal, even exceptionally good hearing. The 21% incidence of ototoxicity we observed is substantial and higher than previously reported. However, our finding of normal hearing in children with equal AG exposure strongly suggests that other unknown factors, possibly genetic susceptibility, influence this outcome. CONCLUSIONS: We recommend comparable auditory testing in all CFpatients with high AG exposures. Genetic analysis may help explain the dichotomy in response to AGs found.
Authors: Angela C Garinis; Douglas H Keefe; Lisa L Hunter; Denis F Fitzpatrick; Daniel B Putterman; Garnett P McMillan; Jeffrey A Gold; M Patrick Feeney Journal: Ear Hear Date: 2018 Jan/Feb Impact factor: 3.570
Authors: Daniel J Fox; Morris D Cooper; Cristian A Speil; Melissa H Roberts; Susan C Yanik; Robert P Meech; Tim L Hargrove; Steven J Verhulst; Leonard P Rybak; Kathleen C M Campbell Journal: J Cyst Fibros Date: 2015-07-10 Impact factor: 5.482
Authors: Angela C Garinis; Campbell P Cross; Priya Srikanth; Kelly Carroll; M Patrick Feeney; Douglas H Keefe; Lisa L Hunter; Daniel B Putterman; David M Cohen; Jeffrey A Gold; Peter S Steyger Journal: J Cyst Fibros Date: 2017-02-24 Impact factor: 5.482
Authors: Min Dong; Anna V Rodriguez; Chelsea A Blankenship; Gary McPhail; Alexander A Vinks; Lisa L Hunter Journal: J Antimicrob Chemother Date: 2021-10-11 Impact factor: 5.790
Authors: Chelsea M Blankenship; Lisa L Hunter; M Patrick Feeney; Madison Cox; Lindsey Bittinger; Angela C Garinis; Li Lin; Gary McPhail; John P Clancy Journal: Am J Audiol Date: 2021-01-19 Impact factor: 1.636